Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH

Treatment of Nonalcoholic fatty liver disease (NAFLD) constitutes an unmet clinical need owing to the relatively limited efficacy of both novel and readily available metabolic medications, thus warranting pathobiological investigations on the mechanisms of single or combination regimens. In this con...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Endocr Soc
Asıl Yazarlar: Perakakis, Nikolaos, Stefanakis, Konstantinos, Feigh, Michael, Veidal, Sanne S, Mantzoros, Christos S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2021
Konular:
Cardiovascular Endocrinology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089912/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.642
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller